Evidence map›Paper›PMID 42564741›Full record

ArticleChemical science2026

Antibody-mediated recognition of chiral poly(2-oxazoline) nanorods driven by enantioselectivity.

David Pizzi, James Humphries, Feifei Liu, John R Finnegan, Jiaying Li, Nicholas L Fletcher, Craig A Bell, Kristofer J Thurecht, Kristian Kempe

Abstract read
In one paragraph

Article in Chemical science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

David PizziDrug Delivery, Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences, Monash University Parkville VIC 3052 Australia kristian.kempe@monash.edu.ORCID https://orcid.org/0000-0003-3116-6946
James HumphriesCentre for Advanced Imaging (CAI) and Australian Institute for Bioengineering and Nanotechnology, and ARC Research Hub for Advanced Manufacture of Targeted Radiopharmaceuticals, The University of Queensland St. Lucia QLD 4072 Australia k.thurecht@uq.edu.au.ORCID https://orcid.org/0000-0002-2603-6947
Feifei LiuCentre for Advanced Imaging (CAI) and Australian Institute for Bioengineering and Nanotechnology, and ARC Research Hub for Advanced Manufacture of Targeted Radiopharmaceuticals, The University of Queensland St. Lucia QLD 4072 Australia k.thurecht@uq.edu.au.
John R FinneganDrug Delivery, Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences, Monash University Parkville VIC 3052 Australia kristian.kempe@monash.edu.ORCID https://orcid.org/0000-0002-2848-5025
Jiaying LiDrug Delivery, Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences, Monash University Parkville VIC 3052 Australia kristian.kempe@monash.edu.ORCID https://orcid.org/0009-0007-7656-3773
Nicholas L FletcherCentre for Advanced Imaging (CAI) and Australian Institute for Bioengineering and Nanotechnology, and ARC Research Hub for Advanced Manufacture of Targeted Radiopharmaceuticals, The University of Queensland St. Lucia QLD 4072 Australia k.thurecht@uq.edu.au.ORCID https://orcid.org/0000-0002-2993-833X
Craig A BellCentre for Advanced Imaging (CAI) and Australian Institute for Bioengineering and Nanotechnology, and ARC Research Hub for Advanced Manufacture of Targeted Radiopharmaceuticals, The University of Queensland St. Lucia QLD 4072 Australia k.thurecht@uq.edu.au.ORCID https://orcid.org/0000-0002-8986-2795
Kristofer J ThurechtCentre for Advanced Imaging (CAI) and Australian Institute for Bioengineering and Nanotechnology, and ARC Research Hub for Advanced Manufacture of Targeted Radiopharmaceuticals, The University of Queensland St. Lucia QLD 4072 Australia k.thurecht@uq.edu.au.ORCID https://orcid.org/0000-0002-4100-3131
Kristian KempeDrug Delivery, Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences, Monash University Parkville VIC 3052 Australia kristian.kempe@monash.edu.ORCID https://orcid.org/0000-0002-0136-9403

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chirality critically governs the pharmacodynamics and clinical performance of small molecule drugs, yet its role in governing bio-nano interactions of synthetic polymeric nanocarriers has remained largely unexplored. Surface grafting with hydrophilic, biocompatible "stealth" polymers such as poly(ethylene glycol) (PEG) is a critical design strategy for nanomedicines intended to reduce nonspecific biological interactions and achieve prolonged circulation. However, the rising prevalence of anti-PEG antibodies has driven the search for fundamentally new design principles, mostly focused on substituting PEG with an entirely different polymer type. Poly(2-oxazoline)s (POx) constitute a versatile class of biocompatible synthetic polymers that uniquely enable access to numerous water-soluble macromolecules that can be rendered chiral, an attribute rarely accessible in synthetic stealth polymers. Here, we report the fabrication of crystalline-core nanorods bearing a chiral poly(2,4-dimethyl-2-oxazoline) (PdMeOx) corona

Identifiers

PMID42564741
PMCPMC13444271

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.